Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24009068 | 0.86 | EGFR (0.41) | SLC6A3HPGDSEGFRERBB2 | |
| SCHEMBL24009072 | 0.83 | SLC6A3 (0.40) | SLC6A3HPGDSEGFRERBB2PLAU | |
| SCHEMBL11701895 | 0.75 | DYRK1A (0.41) | EGFRERBB2PLAUHTT | |
| SCHEMBL24009065 | 0.69 | ALDH1A1 (0.43) | SLC6A3HPGDSEGFRERBB2SRC | |
| SCHEMBL17603410 | 0.68 | ALDH1A1 (0.49) | — | |
| SCHEMBL1344423 | 0.67 | LRRK2 (0.54) | EGFRERBB2MAP2K1HTT | |
| SCHEMBL28479914 | 0.67 | PARP1 (0.36) | — | |
| SCHEMBL30666122 | 0.67 | MAP2K1 (0.36) | SLC6A3HPGDSEGFRERBB2SRC | |
| SCHEMBL24009148 | 0.67 | HPGDS (0.55) | SLC6A3HPGDSEGFRERBB2SRC | |
| SCHEMBL26656463 | 0.67 | MAP2K1 (0.36) | SLC6A3HPGDSEGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2021225969-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | SLC6A3 3584/4885HPGDS 353/4885EGFR 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.